Mumps and Male Fertility: Orchitis Risk, Sterility Rates, and Vaccination

Mumps Orchitis

  • Occurs in 15–30% of post-pubertal males with mumps (rare in prepubertal).
  • Usually unilateral (70–90%); bilateral in 10–30%.
  • Onset: 4–8 days after parotitis; may precede or occur without parotitis.

Sterility Risk

  • Testicular atrophy: 30–50% of affected testes.
  • Clinical sterility (azoospermia): Rare—estimated <1% of all mumps cases; ~10–15% of bilateral orchitis cases.
  • Subfertility (reduced count/motility): More common, often transient.

Mechanism

Viral invasion → seminiferous tubule inflammation, edema, pressure necrosis → fibrosis. Leydig cells (testosterone) usually spared.

Prevention

  • MMR vaccine: 2 doses (12–15 mo, 4–6 yr); 88% effective against mumps.
  • Outbreak settings: Third dose recommended for at-risk groups.
  • Post-exposure: Vaccine not effective; immune globulin not indicated.

Management

  • Supportive: Scrotal support, NSAIDs, cold packs, bed rest.
  • Corticosteroids: Not routinely recommended; limited evidence.
  • Semen analysis: At 3–6 months post-recovery if fertility concern.

Vaccination is the most effective strategy to prevent mumps and its reproductive complications.

Pregnancy & Health - Related Articles